Velomedix is a private medical device company in Menlo Park, CA created to realize the clinical potential of mild Therapeutic Hypothermia (TH) in patients suffering from acute vascular insults. These include heart attack, cardiac arrest, and, potentially, ischemic stroke patients. Therapeutic Hypothermia has been shown to reduce the ischemic and reperfusion effects in these costly and debilitating conditions.

Other settings where TH has been investigated and/or demonstrated to be an effective therapy include traumatic brain injury, fever reduction in post-neurosurgical patients, spinal cord injury, hepatic encephalopathy, comatose meningitis, septic shock, acute respiratory distress syndrome, contrast induced nephropathy, sub-arachnoid hemorrhage, and neonatal ischemic encephalopathy.

Unlike other cooling approaches, Velomedix’s unique technology can rapidly reduce patient temperatures to therapeutic levels. In clinical studies outside the US, the system has achieved therapeutic temperatures in less than fifteen minutes on average.1 This ultrafast cooling rate may therefore make TH an effective enhancement to the time-sensitive treatments of these patients. Velomedix is currently investigating this hypothesis for heart attack patients (Acute Myocardial Infarctions) with the ultimate goal of substantially reducing infarct size which, in turn, may improve patients’ lives and lower healthcare costs.

Caution: Investigational device in the United States. Limited by Federal (United States) law to investigational use.

Velomedix APLS Indication For Use: The Velomedix Automated Peritoneal Lavage System (APLS) is intended to induce, maintain, and reverse mild hypothermia to treat patients with ST elevated myocardial infarction (STEMI) by controlling the body’s core temperature at a desired target level by lavaging the peritoneal cavity with temperature-controlled fluid.

1. Data on file. Clinical trials outside the United States.


PML-2935 Rev. G